A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Lin X, David CA, Donnelly JB, Michaelides M, Chandel NS, Huang X, Warrior U, Weinberg F, Tormos KV, Fesik SW, Shen Y (2008) Proc Natl Acad Sci U S A 105: 174-9 Identifying mechanism-of-action targets for drugs and probes. Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK (2012) Proc Natl Acad Sci U S A 109: 11178-83 MALDI-MS-based imaging of small molecules and proteins in tissues. Reyzer ML, Caprioli RM (2007) Curr Opin Chem Biol 11: 29-35 Technologies for controlled, local delivery of siRNA. Sarett SM, Nelson CE, Duvall CL (2015) J Control Release 218: 94-113 Preclinical drug discovery research and training at Vanderbilt. Lindsley CW, Weaver D, Jones C, Marnett L, Conn PJ (2007) ACS Chem Biol 2: 17-20 Etoposide: four decades of development of a topoisomerase II inhibitor. Hande KR (1998) Eur J Cancer 34: 1514-21 Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Lopes LB, Brophy CM, Furnish E, Flynn CR, Sparks O, Komalavilas P, Joshi L, Panitch A, Bentley MV (2005) Pharm Res 22: 750-7 Cytochrome P450s and other enzymes in drug metabolism and toxicity. Guengerich FP (2006) AAPS J 8: E101-11 The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Lindsley CW, Barnett SF, Layton ME, Bilodeau MT (2008) Curr Cancer Drug Targets 8: 7-18 CMT-3. CollaGenex. Fingleton B (2003) Curr Opin Investig Drugs 4: 1460-7 Investigation of different formulations for drug delivery through the nail plate. Vejnovic I, Simmler L, Betz G (2010) Int J Pharm 386: 185-94 Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening. Madoux F, Janovick JA, Smithson D, Fargue S, Danpure CJ, Scampavia L, Chen YT, Spicer TP, Conn PM (2015) Assay Drug Dev Technol 13: 16-24 Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. Kuehl PJ, Cherrington A, Dobry DE, Edgerton D, Friesen DT, Hobbs C, Leach CL, Murri B, Neal D, Lyon DK, Vodak DT, Reed MD (2014) AAPS PharmSciTech 15: 1545-50
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.